Bavarian Nordic A/S represents a strong set of values and corporate philosophy. The company is committed to delivering innovative and effective solutions for preventing and treating serious infectious diseases, including cancer immunotherapies. Bavarian Nordic A/S prioritizes patient health and safety, investing in research and development to advance its product pipeline. With a focus on collaboration and partnerships, the company aims to foster scientific advancements in the field of immunotherapy. Bavarian Nordic A/S strives to create long-term value for its shareholders while upholding the highest standards of integrity, transparency, and ethical conduct.

Bavarian Nordic A/S is primarily present in Denmark, where its headquarters are located. Additionally, the company has a strong presence in the United States, where it conducts various operations. Bavarian Nordic A/S also has a growing presence in Canada and several European countries, including Germany, France, and the United Kingdom. With its expanding global reach, Bavarian Nordic A/S is establishing a significant presence in the field of biotechnology and vaccine development.

Bavarian Nordic A/S, a leading biotechnology company, has achieved several significant milestones. One notable accomplishment is the development and commercialization of its innovative smallpox vaccine, IMVANEX®. This vaccine has been stockpiled by governments worldwide, providing a crucial defense against bioterror threats. Additionally, Bavarian Nordic achieved successful clinical trials for its promising prostate cancer immunotherapy, PROSTVAC®, demonstrating encouraging results in improving overall survival rates. The company has also formed strategic partnerships with global pharmaceutical companies, further validating its strong pipeline and expanding its reach in the biopharmaceutical industry. Bavarian Nordic A/S continues to make remarkable strides in advancing cutting-edge vaccines and therapies, solidifying its position as an industry leader.

Bavarian Nordic A/S is a renowned biotechnology company headquartered in Denmark. Founded in 1994, the company specializes in developing innovative vaccines to combat infectious diseases and cancer. Bavarian Nordic A/S gained significant recognition for its unique expertise in the development of vaccines against bioterrorism threats, including smallpox and Ebola. With a strong focus on research and development, the company has established partnerships with various government agencies and international organizations. They have successfully commercialized several vaccines, such as IMVAMUNE® (smallpox) and PROSTVAC® (prostate cancer). Bavarian Nordic A/S continues to make remarkable advancements in the field of biotechnology, aiming to improve global health through its cutting-edge vaccine solutions.

The main competitors of Bavarian Nordic A/S in the market are GlaxoSmithKline (GSK), Merck & Co., Inc., and Johnson & Johnson. These companies operate in the same biopharmaceutical industry and offer products and services similar to Bavarian Nordic A/S. Being a prominent player in the market, Bavarian Nordic A/S faces competition from these industry leaders in terms of research and development, product innovation, and market share. Despite the competition, Bavarian Nordic A/S has established itself as a strong contender, leveraging its expertise in developing innovative vaccines and immunotherapies.

Bavarian Nordic A/S is primarily active in the biotechnology and pharmaceutical industries.

The business model of Bavarian Nordic A/S is focused on researching, developing, manufacturing, and commercializing vaccines for infectious diseases. The company specializes in immunotherapies and has extensive expertise in vaccine adjuvants and recombinant protein-based vaccines. Bavarian Nordic A/S collaborates with various organizations, including governments, pharmaceutical companies, and research institutions, to advance the development of novel vaccines. The company aims to address unmet medical needs and improve global public health through its innovative vaccine solutions. Bavarian Nordic A/S strives to leverage its scientific knowledge and technological capabilities to provide effective and safe vaccine options for the prevention and treatment of diseases.

Bavarian Nordic A/S의 P/E 비율은 10.51입니다.

Bavarian Nordic A/S의 P/S 비율은 2.25입니다.

Bavarian Nordic A/S에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Bavarian Nordic A/S 매출은 6.75 조. DKK입니다.

예상되는 Bavarian Nordic A/S 이익은 1.44 조. DKK입니다.

Bavarian Nordic A/S is a Danish company specializing in the development and marketing of vaccines. The company was founded in 1994 in Bavaria, hence the name, and is now headquartered in Copenhagen. In addition to vaccines, the company also specializes in the distribution of specialized therapies and diagnostic systems for diseases such as cancer and hepatitis. The products are divided into three business areas: vaccines, therapies, and biodefense products. The company works closely with various authorities and organizations to promote the marketing of its products and has established strategic partnerships with other pharmaceutical companies and biotech firms. Bavarian Nordic A/S invests around 15% of its revenue annually in research and development to expand its portfolio in each business area. The company has built a solid business model and has become a leading provider of smallpox vaccines and an important player in the biodefense industry. Through collaboration with health authorities and partnerships with other pharmaceutical companies, Bavarian Nordic A/S has achieved a strong market position in the biomedical research and development field.

Bavarian Nordic A/S은(는) 연간 번의 배당을 통해 0 DKK의 배당금을 지급합니다.

Bavarian Nordic A/S의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Bavarian Nordic A/S의 ISIN은 DK0015998017입니다.

Bavarian Nordic A/S의 WKN은 917165입니다.

Bavarian Nordic A/S의 티커는 BAVA.CO입니다.

지난 12개월 동안 Bavarian Nordic A/S은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Bavarian Nordic A/S은(는) 0 DKK의 배당금을 지급할 것으로 예상됩니다.

Bavarian Nordic A/S의 현재 배당 수익률은 입니다.

Bavarian Nordic A/S은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Bavarian Nordic A/S은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 DKK의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Bavarian Nordic A/S은 '건강' 섹터에 속합니다.

Bavarian Nordic A/S의 마지막 배당금을 0 DKK만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Bavarian Nordic A/S는 0 DKK를 배당금으로 지급했습니다.

Bavarian Nordic A/S의 배당금은 DKK에 지급됩니다.